- Aurobindo Pharma‘s 4Q Net income was 9.09 billion rupees, beating the estimated 8.39 billion rupees, indicating a year-on-year increase of 80%.
- The revenue reported stood at 75.8 billion rupees, showing a year-on-year increase of 17% and exceeding the estimate of 73.17 billion rupees.
- However, Active Pharmaceutical Ingredients sales slightly fell behind projections at 10.19 billion rupees compared to the estimated 10.5 billion rupees.
- The quarter’s total costs rose by 8.2% year-on-year to 63.5 billion rupees.
- The finance cost saw a dramatic year-on-year increase of 61%, standing at 894.3 million rupees, far exceeding the estimated 669.1 million rupees.
- Other income just saw minimal growth of 0.7% year-on-year, with a reported 1.36 billion rupees.
- Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were higher than estimated, 16.87 billion rupees against an estimate of 15.17 billion rupees.
- The EBITDA margin was reported at 22.3%, outperforming the estimate of 20.6%.
- However, research and development (R&D) expenses were slightly lower than expected, with reported expenses of 3.92 billion rupees against an estimate of 4.08 billion rupees.
- Lastly, 22 buys, 5 holds, and 3 sells were reported.
A look at Aurobindo Pharma Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 3 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using the Smartkarma Smart Scores have evaluated Aurobindo Pharma‘s long-term outlook based on various factors. With a strong Value score of 4, the company is deemed to offer good value for investors. Aurobindo Pharma also scores well in terms of Resilience and Momentum, both receiving a score of 4. This suggests that the company has shown resilience in challenging times and has positive momentum for future growth.
However, Aurobindo Pharma‘s Growth score of 2 indicates a potential area of concern for investors, as the company may have slower growth prospects. Additionally, the Dividend score of 3 suggests that the company’s dividend payouts may not be as attractive compared to other factors. Overall, Aurobindo Pharma‘s strong performance in Value, Resilience, and Momentum bodes well for its long-term prospects in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
